PMA device
Synvisc Hylan G-F 20
Sanofi Genzyme Corp. · Acid, Hyaluronic, Intraarticular (MOZ, Class III) · First FDA decision Jun 9, 2008, newest Jun 9, 2008Knee osteoarthritis
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
PMA pathway
Device trials
32
Naming "Synvisc Hylan G-F"
MAUDE reports
12
Brand "Synvisc Hylan G-F", since 2015
PubMed studies
0
Mentioning "Synvisc Hylan G-F"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Synvisc Hylan G-F 20
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
- SYNVISC HYLAN G-F 20PMA supplement
P940015-S011 · Decided Jun 9, 2008 · 475 days after receipt · Normal 180 Day Track
Device type: Acid, hyaluronic, intraarticular (MOZ) · Orthopedic Surgery
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Synvisc Hylan G-F", any status and sponsor, newest update first.
- Genicular Nerve Radiofrequency Ablation Versus Hyaluronic Acid Injection for Knee Osteoarthritis PainNot yet recruiting
Hospital Universitari Joan XXIII de Tarragona.Academic, hospital or other
NCT07901374 · 70 participants (planned) · Start Nov 2026 · Primary completion May 2028
Device: Intra-articular Hyaluronic Acid · For: Knee Osteoarthritis; Chronic Knee Pain
Sites: Tarragona, Spain
- Comparative Effectiveness and Safety of Two Hyaluronic Acid Products in Knee OsteoarthritisNot yet recruiting
Coordinación de Investigación en Salud, MexicoGovernment (non-federal)
NCT07911696 · 160 participants (planned) · Start Nov 2026 · Primary completion Jun 2027
Device: Hylan G-F 20; Cross-Linked Sodium Hyaluronate · For: Osteoarthritis, Knee
Sites: Mexico City, Mexico
Centro Multidisciplinario para el Desarrollo Especializado de la Investigacion Clinica en Yucatan S.Research network
NCT07692009 · 32 participants · Start Jan 23, 2024 · Primary completion Jun 19, 2026
Device: Hylan G-F 20 · For: Osteoarthritis (OA) of the Knee
Sites: Mérida, Mexico
29 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Synvisc Hylan G-F", and for the whole product code for context.
This brand
12 reports: 1 malfunction, 10 injury, 1 death
Whole product code MOZ
4,975 reports: 669 malfunction, 3,945 injury, 278 death
Newest reports for this brand
- Synvisc Hylan G-F 20Injury
MW6001365 · Received Aug 20, 2026 · Event dated Jul 8, 2026
Device type: Acid, Hyaluronic, Intraarticular (MOZ)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Bacterial Infection; Pain; Swelling/ Edema
- Synvisc Hylan G-F 20Injury
MW6001376 · Received Aug 20, 2026 · Event dated Jul 8, 2026
Device type: Acid, Hyaluronic, Intraarticular (MOZ)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Bacterial Infection; Pain; Swelling/ Edema
- Synvisc Hylan G-F 20Injury
MW6001375 · Received Aug 20, 2026 · Event dated Aug 6, 2026
Device type: Acid, Hyaluronic, Intraarticular (MOZ)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Bacterial Infection; Pain; Swelling/ Edema
2 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-0607-2018 · Started Dec 11, 2017
Reason given: Contamination with Methylbacterium thiocyanatum
Cause as FDA categorized it: Environmental control · Device type: Acid, Hyaluronic, Intraarticular (MOZ)
Published research
The most relevant PubMed records for "Synvisc Hylan G-F"[tiab]. The summary above synthesizes these.
No PubMed record mentions this device by name.
Other devices of this type
Also filed under product code MOZ.
- EUFLEXXA (1% Sodium Hyaluronate)Ferring Pharmaceuticals, Inc. · PMA 2017
- Gel-One(R)Seikagaku Corp. · PMA 2016
- Supartz FxSeikagaku Corp. · PMA 2016
- SupartzSeikagaku Corp. · PMA 2015
- Orthovisc High Molecular Weight HyaluronanAnika Therapeutics, Inc. · PMA 2011
- DurolaneBioventus, LLC · PMA 2020
- MonoviscAnika Therapeutics, Inc. · PMA 2020
- HyalganFidia Farmaceutici S.P.A. · PMA 2008
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.